In a small study, 34% of dialysis patients had vertebral fractures, and patients in the highest tertile of parathyroid hormone level had a nearly 3-fold increased risk of these fractures compared with those in the middle tertile.
New data support aggressive vitamin D repletion to a revised serum 25-hydroxyvitamin D target of at least 51 ng/mL in patients with chronic kidney disease.
Twice as many patients taking a high cinacalcet dose before transplantation required subsequent parathyroidectomy persistent secondary hyperparathyroidism.
Dialysis patients who underwent parathyroidectomy had a 24% greater risk for cardio- and cerebrovascular events than similar patients who did not undergo the surgery.
In 2 small trials of Japanese patients with SHPT on dialysis, evocalcet treatment reduced iPTH to target levels in a majority of patients within 30 to 32 weeks.
